AdvisorShares Trust reports 5.33% stake in Quantum Biopharma
Quantum Biopharma Ltd. reports a Schedule 13G filing showing AdvisorShares Trust beneficially owns 203,564 Class B Subordinate Voting Shares, representing 5.33% of that class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quantum Biopharma Ltd. reports a Schedule 13G filing showing AdvisorShares Trust beneficially owns 203,564 Class B Subordinate Voting Shares, representing 5.33% of that class.
The filing states AdvisorShares Trust holds sole voting and dispositive power over 203,564 shares. The disclosure is signed by the fund's Chief Compliance Officer on 07/08/2026.
Insights
AdvisorShares Trust reports a 5.33% stake in Quantum Biopharma (Class B).
The filing lists 203,564 shares beneficially owned with sole voting and dispositive power. This indicates a passive institutional holding disclosed via Schedule 13G rather than an active acquisition disclosure.
Timing and transactional details are not included; subsequent filings would show any changes in position.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Schedule 13G mean for QNTM investors?
How significant is a 5.33% Class B stake in QNTM?
AI-generated analysis. How Rhea-AI works. Not financial advice.